Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biropepimut-S in high-risk oral cavity cancer
NCT02873819Phase 2Completed
- Sponsor
- Gliknik
- Start
- Mar 2017
- Primary completion
- May 2021
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in squamous cell carcinoma of the oral cavity (OSCC) comparing GL-0817 with Placebo (2 arms). Primary endpoint: Disease-free interval at 2 years. Started Mar 2017; status: completed.
02
Drugs
biropepimut-s
03
Conditions
squamous cell carcinoma of the oral cavity (OSCC)
Beyond the preview
Go deeper on NCT02873819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873819.